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tions, health care utilization, and costs in 12-month follow-up period were as-
sessed. Complications included microvascular (e.g. diabetic retinopathy), macro-
vascular (e.g. atherosclerosis), and other diabetic complications. Cox proportional
hazards models were used to compare complication rates, adjusting for baseline
characteristics. Generalized linearmodels/two-partmodelswere similarly used for
utilizations and costs. RESULTS: The study included 15,139 patients (47.0% female;
mean age 52.6 [SD8.1]) receiving DPP4i combinations and 41,602 patients (42.4%
female; mean age 51.9 [SD8.3]) receiving SU combinations. At baseline, DPP4i
patients had higher rates ofmedication use than SU patients (MET: 61.7% vs. 40.4%;
TZD: 23.0% vs. 11.8%; lipid-lowering: 53.2% vs. 35.4%; number of different medica-
tions: 7.2 [SD5.1] vs. 5.3 [SD4.9], respectively; all P0.0001). After adjustment,
hazard ratios of complications were significantly lower for patients treated with
DPP4i combinations (microvascular complications: 0.872, P0.0001;macrovascular
complications: 0.933, P0.0015; other complications: 0.921, P0.0001). DPP4i pa-
tients also had lower adjusted diabetes-related utilization incidence rate ratios
(hospitalization: 0.76; ER visits: 0.69; outpatient visits: 0.87; all P0.0001). DPP4i
patients incurred higher mean diabetes-related prescription drug costs ($1,629 vs.
$476, P0.0001) but lower all-cause medical services costs ($6731 vs. $7251,
P0.0001). CONCLUSIONS: Compared to SU combinations, DPP4i combinations are
associated with lower rates of diabetic complications and health care utilization.
While patients onDPP4i combination incur higher diabetes-related drug costs, they
were found to have lower all-cause medical-services costs.
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OBJECTIVES: The prevalence of diabetes in China is rising, and was recently esti-
mated as 9.7% in The China National Diabetes andMetabolic Disorders Study, with
a large proportion of patients previously undiagnosed. The costs of treating com-
plications in all patients and managing the disease in diagnosed patients are high.
The aim of this study was to estimate the annual cost of illness for all patients and
lifetime diabetes costs for diagnosed patients in China. METHODS: A model was
developed to estimate the cost of diabetes for 2011. Diabetes complication costs
were derived from hospital surveys in Beijing and Chengdu. Diabetes treatment
strategies were based on the intensive arm of the UK Prospective Diabetes Study
(UKPDS). The annual incidence and prevalence rates for major diabetic complica-
tions, including cardiovascular, renal, ocular, foot ulcer, neuropathy and treat-
ment-related events, were derived from international studies of diagnosed pa-
tients with baseline disease duration of less than ten years, including the UKPDS.
All patients were at risk of incurring complication costs, and only diagnosed pa-
tients could incur treatment and management costs. For diagnosed patients life-
time cost projections were made, discounted by 3% annually, using a validated
diabetes model. RESULTS: The 2011 cost of diabetes was estimated as CNY 13,326
per diagnosed and CNY 4,727 per undiagnosed patient, with the difference attrib-
utable to diabetes treatment and management costs. Based on a total population
approaching 1.4 billion and previously reported disease prevalence rates, the na-
tional cost of diabetes in 2011 was estimated as CNY 1,214 billion. In diagnosed
patients, a lifetime cost of CNY 301,716 per patient was estimated (or CNY 18,253
billion nationally); diabetes complications comprised 53% of total costs.
CONCLUSIONS: The costs of diabetes in China are high. Based on a Gross Domestic
Product (GDP) of CNY 47,156.4 billion for 2011, appropriate care for every diabetic in
China would cost 2.6% of GDP.
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OBJECTIVES: Data from the 2006 Malaysian National Health Morbidity Survey
showed that the overall prevalence of diabetes in Malaysia is over 11%. The high
prevalence of diabetes and themanagement of diabetes-related complications has
considerable implications in terms of health care spending, with 16% of overall
health care spending inMalaysia attributed to themanagement of diabetes in 2010.
The objective of the study was to estimate current direct costs associated with
diabetes-related complications in Malaysia.METHODS:Most direct costs of diabe-
tes complications were derived from interviews with three key opinion leaders in
the field of diabetes in Malaysia. Dialysis costs were sourced from published liter-
ature.Mean costswere then estimated calculated for first and subsequent years for
each event/complication. All costs are presented in 2011 Malaysian Ringgits (MYR)
(converted to US dollars [USD], exchange rate USD 1 to MYR 3.14). RESULTS: End-
stage renal disease was associated with the highest annual per patient costs, with
mean first year costs for hemodialysis and peritoneal dialysis being MYR23,500
(USD7,070) and MYR36,000 (USD11,465) per year, respectively. Costs of renal trans-
plant were MYR26,000 (USD8,280) in the year of transplant andMYR3,000 (USD955)
per year in subsequent years. Other complications associatedwith high direct costs
were amputation and prosthesis (MYR425 andMYR3,750, respectively [USD135 and
USD1,194, respectively]), cataract operation (MYR3,221, USD1,026) and myocardial
infarction (MYR1,233 [USD393] in year of event and MYR367 [USD117] per year in
subsequent years). Additionally, neuropathy was associated with mean costs of
MYR900 (USD287) in the first year and MYR675 (USD215) per year thereafter.
CONCLUSIONS: Diabetes is associated with a substantial economic burden in Ma-
laysia, and themanagement of diabetes related complications is likely to represent
a significant proportion of the overall costs. The cost data reported in this study
represents a useful resource for future economic evaluations of diabetes in Malay-
sia.
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OBJECTIVES: Indonesia has the fourth highest number of cases of diabetesmellitus
in the world. Estimates from 2010 indicated that approximately 7,000,000 people in
Indonesia had diabetes. Although diabetes-related complications are associated
with a considerable economic burden, there is a paucity of data on the costs of
diabetes in Indonesia. The aim of the present studywas to estimate the direct costs
associatedwithmanaging diabetes-related complications from a health care payer
perspective in Indonesia. METHODS: Literature review of EMBASE, PubMed, the
Cochrane Library and grey literature provided few publications to inform cost es-
timates. Costs were evaluated based on interviews with local expert physicians
and were collected for the first year of treatment and each subsequent year per
event/complication. Costs were classified into six main groups: cardiovascular
complications, renal complications, acute events, eye-disease, neuropathy and di-
abetic foot complications, and concomitant medications. Costs were expressed in
2011 Indonesian Rupiah (IDR) with US dollar (USD) conversions (exchange rate
USD1 to IRD8,940). RESULTS:Myocardial infarction was the most costly cardiovas-
cular complication with a first year cost of IDR202.7 million (USD22,673), followed
by stroke, unstable angina and heart failure. Renal complications were also signif-
icant contributors of cost with transplantation estimated to cost approximately
IDR192.5 million (USD21,532) in the first year and IDR45 million (USD5,033) in each
subsequent year. Hemodialysis cost over IDR89.3 million (USD9,994) annually and
peritoneal dialysis cost over IDR57.1million (USD6,391) each year. Themost expen-
sive ocular procedure was cataract surgery (IDR5.1 million [USD573]). Lower limb
amputation was themost costly of the diabetic foot complications (IDR21.2million
[USD2,375]). CONCLUSIONS: Estimates of complication costs suggest that the 7
million patients with diabetes represent a substantial economic burden in Indone-
sia. The data collected in this study represent a valuable resource to investigate the
economic impact of diabetes treatments in the Indonesian setting.
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OBJECTIVES: Diabetes is associated with a substantial and growing clinical and
economic burden in India, accounting for approximately 11% of national health
care expenditure in 2010. Moreover, the management of diabetes-related compli-
cations is the main contributor to the overall cost of the disease. The objective of
the study was to obtain current direct costs for the management of diabetes-re-
lated complications in India.METHODS: Direct costs of diabetes-related complica-
tions were derived from interviews with three expert diabetologists based in India,
with the exception of the costs of renal procedures, which were derived from
published, country-specific literature. Mean values based on all experts’ estimates
were calculated for first and subsequent years for each complication. Costs were
classified into 6 groups (management, cardiovascular complications, renal-compli-
cations, acute-events, eye-disease and neuropathy/foot ulcers). Costs are pre-
sented in 2011 Indian Rupees (INR) with equivalent US dollar (USD) values (ex-
change rate USD1 to INR50.23). RESULTS: At an individual patient level the most
expensive diabetes-related complication was end-stage renal disease, where both
peritoneal dialysis and hemodialysis were associated with direct annual costs of
INR788,059 and INR755,223, respectively, and renal transplant was associated with
costs of INR577,910 (USD11,505) in the year of transplant and INR295,522 (USD5,883)
in each subsequent year. The direct cost of cardiovascular complications was also
high; for examplemyocardial infarction cost approximately INR162,500 (USD3,235)
in the year of event and INR16,500 (USD328) in subsequent years. Gangrene
(INR55,000 [USD1,095] per event) and infect ulcer (INR27,500 [USD547] per event)
had the highest costs of the diabetic foot complications. CONCLUSIONS: In India,
direct costs associated with themanagement of diabetes-related complications, in
particular renal and cardiovascular complications, contribute significantly to the
economic burden associated with diabetes. Costs presented in this study will pro-
vide useful data for economic evaluations of diabetes interventions in India.
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OBJECTIVES: To estimate the direct medical cost for diabetes mellitus (DM) related
complications in China. METHODS: Data were obtained from a cross-sectional
survey of 20 internists of endocrine and metabolism departments in 20 hospitals
from September to November in 2011 in 9 cities of China. 11 internists worked in
tier 3 hospitals and 9 worked in tier 2 hospitals. All the internists who are depart-
ment director or deputy director were asked to give the average costs of complica-
tions treatment according to their clinical practice and retrospective medical re-
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